These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11987442)

  • 1. Cost and effectiveness of hip protectors among the elderly.
    Segui-Gomez M; Keuffel E; Frick KD
    Int J Technol Assess Health Care; 2002; 18(1):55-66. PubMed ID: 11987442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations?
    Honkanen LA; Mushlin AI; Lachs M; Schackman BR
    J Am Geriatr Soc; 2006 Nov; 54(11):1658-65. PubMed ID: 17087691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-benefit analysis of external hip protectors in the nursing home setting.
    Honkanen LA; Schackman BR; Mushlin AI; Lachs MS
    J Am Geriatr Soc; 2005 Feb; 53(2):190-7. PubMed ID: 15673340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents.
    Singh S; Sun H; Anis AH
    J Rheumatol; 2004 Aug; 31(8):1607-13. PubMed ID: 15290742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased use of hip protectors in nursing homes: economic analysis of a cluster randomized, controlled trial.
    Meyer G; Wegscheider K; Kersten JF; Icks A; Mühlhauser I
    J Am Geriatr Soc; 2005 Dec; 53(12):2153-8. PubMed ID: 16398901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of hip protector use on a geriatric ward in Germany: a Markov model.
    Stollenwerk B; Bartmus T; Klug F; Stock S; Müller D
    Osteoporos Int; 2015 Apr; 26(4):1367-79. PubMed ID: 25572047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
    Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
    Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
    J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.
    Zeliadt SB; Etzioni RD; Penson DF; Thompson IM; Ramsey SD
    Am J Med; 2005 Aug; 118(8):850-7. PubMed ID: 16084177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of hormone therapy in younger and older postmenopausal women.
    Salpeter SR; Buckley NS; Liu H; Salpeter EE
    Am J Med; 2009 Jan; 122(1):42-52.e2. PubMed ID: 19114171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
    Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of cataract surgery in the second eye.
    Busbee BG; Brown MM; Brown GC; Sharma S
    Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional variation in the cost effectiveness of childhood hepatitis A immunization.
    Jacobs RJ; Greenberg DP; Koff RS; Saab S; Meyerhoff AS
    Pediatr Infect Dis J; 2003 Oct; 22(10):904-14. PubMed ID: 14551492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of preventing hip fractures by hip protectors in elderly institutionalized residents in Germany.
    Gandjour A; Weyler EJ
    Value Health; 2008 Dec; 11(7):1088-95. PubMed ID: 19602215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Could a policy of provision of hip protectors to elderly nursing home residents result in cost savings in acute hip fracture care? The case of Ontario, Canada.
    Sawka AM; Gafni A; Boulos P; Beattie K; Papaioannou A; Cranney A; Hanley DA; Adachi JD; Cheung A; Papadimitropoulos EA; Thabane L
    Osteoporos Int; 2007 Jun; 18(6):819-27. PubMed ID: 17221294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.